Cover Image
市場調查報告書

中國的醫藥品製造業

China pharmaceutical manufacturing industry, 2016

出版商 Reports From China 商品編碼 243613
出版日期 內容資訊 英文 184 Pages
商品交期: 請詢問到貨日
價格

Notice: The original report is written in Chinese. Please ask us for more information regarding delivery time.

Back to Top
中國的醫藥品製造業 China pharmaceutical manufacturing industry, 2016
出版日期: 2016年03月04日 內容資訊: 英文 184 Pages
簡介

本報告提供中國的醫藥品的製造業最新趨勢相關調查,提供國際·國內市場趨勢,及產業的實際狀態·實際成果(企業數,資產額,整體生產額等),競爭環境,再加上主要企業概要(基本資料,經營情形,資產·負債,支出·費用),投資環境,技術開發趨勢,到的發展趨勢預測等相關分析,並將結果概述為以下內容。

第1部分 產業概況

第1章 醫藥品製造業的定義與發展

  • 市場與主要產品定義
  • 產業的主要的特徵和發展歷史

第2章 宏觀經濟環境與其影響

  • 目前宏觀經濟的發展和趨勢
  • 最新的產業政策與相關法規·規定
  • 上游/下游過程產業的發展情形

第3章 國際市場分析

  • 國際市場目前發展情形
  • 主要國家·地區的發展水準
  • 國際市場趨勢分析

第4章 中國國內市場分析

  • 國內市場目前發展情形
  • 國內市場趨勢
  • 主要產業及各產業的市場發展情形

第2部分 基本的事項

第5章 規模分析

  • 企業總數
  • 虧損的企業數
  • 產業整體虧損金額
  • 員工數

第6章 資產分析

  • 資產總額
  • 固定資產總額
  • 流動資產總額

第3部分 經營情形

第7章 整體生產額分析

  • 整體生產額
  • 各地區整體生產額
  • 前20大企業比較(根據總產量)

第8章 銷售收益分析

  • 銷售收益總額
  • 各地區銷售收益額
  • 前20大企業比較(銷售收益為主)

第9章 整體利益分析

  • 整體利益額
  • 各地區整體利益額
  • 前20大企業比較(整體利益額為主)

第10章 進出口分析

  • 出口/進口的每月總額
  • 各用戶·各合作國家的進出口額
  • 出口商品/進口商品的各產品領域的詳細內容

第4部分 競爭環境

第11章 競爭環境分析

  • 各地區市場的競爭環境
  • 各企業的市場佔有率比較

第12章 主要企業的競爭力比較分析

  • 主要企業的整體資產比較分析
  • 主要企業的員工數比較分析
  • 主要企業的年度收益比較分析
  • 主要企業的出口額比較分析
  • 主要企業的整體利益額比較分析
  • 主要企業的整體競爭力比較分析

第5部分 主要企業

第13章 主要企業比較分析

  • Yangtze River Pharmaceutical Group Co., Ltd
  • Harbin Pharmaceutical Group Co., Ltd
  • Jilin Xiuzheng Pharmaceutical Group Co., Ltd
  • CSPC Pharmaceutical Group Limited
  • Weigao Holding Company Limited
  • Northeast Pharmaceutical Group Co., Ltd
  • Bayer HealthCare Co., Ltd
  • North China Pharmaceutical Group Corp.
  • Xinxiang Liuzhuang Agriculture- Industry-Commerce United Company
  • Xi'an Janssen Pharmaceutical Ltd
  • Henan Caixin Group Co., Ltd
  • Yishui Dadi Corn Developing Co., Ltd
  • Pfizer Pharmaceuticals Limited
  • Novo Nordisk (China) Pharmaceuticals Co., Ltd
  • Tianjin Zhongxin Pharmaceutical Group Corporation Limited
  • Reyoung Pharmaceutical Co., Ltd
  • Shijiazhuang PharmaGroup Zhongrun Pharmaceutical (Inner Mongolia) Co., ltd
  • Shanghai Roche Pharmaceuticals Limited
  • Zhejiang Medicine Co., Ltd Xinchang Pharmaceutical Factory
  • Huiren Group Co., Ltd

第6章 產業策略

第14章 產業發展上的瓶頸和解決的辦法

  • 產業發展上的瓶頸
  • 解決的辦法

第15章 企業的發展策略的分析與建議

  • 企業的產業策略的分析與建議
  • 企業的行銷策略的分析與建議

第7部分 市場投資

第16章 投資活動係數與投資收益比較·分析

  • 產業活動係數比較分析
  • 投資收益比較·分析

第17章 投資環境·投資風險分析

  • 投資環境分析
  • 投資風險分析
  • 投資相關建議

第8部分 技術

第18章 最新技術應用的現況和趨勢

  • 最新技術應用現況
  • 技術開發的趨勢

第9部分 發展與趨勢

第19章 發展趨勢與經營能力的預測

  • 發展趨勢
  • 經營能力預測
  • 見解與建議

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 19536

Pharmaceutical Manufacturing Industry refers to the procedure during which after physical or chemical change raw materials turn into new pharmaceutical products including common traditional Chinese medicine, western medicine and veterinary drugs consisting of pharmaceutical raw materials and hygienic materials.

The manufacturing of active compounds made from chemicals includes: Manufacturing of such active compounds with chemicals as antibiotics, endocrine products, essential vitamins, sulfo-drugs, salicylates, glucose and alkaloid drug substance; chemical pure sugar. Excluding: the manufacturing of blood and plasma and other blood products that are categorized as the manufacturing of biological and biochemical products (code: 2760).

Chemical pharmaceutical manufacturing includes: tablet, injection, capsule, potion, cream, powder, solvent and so on; radiopharmaceuticals. Excluding: the manufacturing of Chinese patent medicine (code: 2740); the manufacturing of veterinary drugs (code: 2750); the manufacturing of biological products and biochemical drugs (code: 2760).

Chinese herbal pieces processing includes: a variety of Chinese herbal medicines made through the manufacturing and formation of Chinese medicine materials; other manufacturing of the extraction of traditional Chinese medicine.

Chinese patent medicine manufacturing includes: honeyed pill, water pills, granules, syrup, plaster, etc. made by the production method of traditional Chinese medicine; tablet, injection, capsule, oral liquid, etc. made by the method of modern pharmaceutical production of traditional Chinese medicine; specially curative medicinal liquor.

Veterinary drug manufacturing includes: animal chemicals, animal antibiotics, animal vaccines, Chinese herbal medicine; feed drugs, aquaculture drugs, etc. Excluding the production of feed additives (growth promoting agent), which is categorized into food and feed additives manufacturing (code: 1494).

The manufacturing of biological and biochemical product includes: genes, cells, enzymes, fermentation engineering drugs, genetic engineering vaccine, new vaccine, vaccine; medicinal amino acids, antibiotics, vitamin, micro ecological preparation medicine; blood products and substitutes; diagnostic reagents: blood grouping reagents, X-ray contrast agent, patient diagnosis reagent; biochemical medicines made of animal liver.

The manufacturing of hygienic materials and medical products includes: surgical dressings, pharmaceutical packing: sticking plaster, absorbent cotton, bandages, etc.; curing materials, biological materials, dental filling materials, orthodontic materials, impression materials, abrasive materials used in treatment of dental adhesives; sterile absorbable hemostatic materials used in surgery and dentistry; bandages, gut and other surgical suture for fracture; gelatin medicinal capsules; the manufacturing of medical polymer materials and products. Excluding: medical gauze manufacturing, listed in cotton and chemical fiber textile processing (code: 1711 ); the manufacturing of glass ampoules, vials and other medical glassware, listed glass manufacturing ( code: 3144 ); aluminum foil production, listed in the production of other daily metal products (code: 3489); production of pharmaceutical packaging composite film, listed in the production of plastic film ( code: 3010 ); the manufacturing of dentures, artificial organs and other provided by dentists, listed in the production of prostheses, artificial organs and implantable device ( code: 3686); medical rubber products, listed in 2920, rubber products manufacturing ,in more detail, the manufacturing of rubber sheet, pipe, tape (code: 2920) and the manufacturing of daily and medical rubber products medical (code: 2950); Plastic products manufacturing, listed in manufacturing of other plastic products (code: 3090).

For the past few years, China has promulgated many reform measures. Those closely relating to the pharmaceutical industry mainly included: basic medical insurance system, drug classification management, GMP certification system, purchase of drugs by centralized bidding, drug price reduction and export rebate rate reduction.

In the first half year of 2015, the overall growth rate of the pharmaceutical industry dropped. Bio-pharmaceutical (including biological detection), medical instrument and medical service enterprises were almost all expected to grow. The rapid development of such three kinds of enterprises shows that China's pharmaceutical industry is making structural adjustment based on the support of policies. The whole industry has an obvious development trend towards technology improvement.

The first future trend of the pharmaceutical industry is: the industrial gross will continue to grow, and present size is huge at a multi trillion level.

The second future trend of the pharmaceutical industry is industry integration. Integration of the circulation in the field will be intensified to realize concentration rapidly. The market survey analysis report on pharmaceutical industry shows that in the United States, three of the circulation enterprises account for 96% of the drug market. China has tens of thousands of circulation enterprises most of which will be integrated sooner or later.

The third future trend of pharmaceutical industry: Industrial upgrading. The first is the upgrading of products, such as prescription, technology, standard, and dosage form etc.

China pharmaceutical manufacturing industry, 2016 provides a complete set of the industry data, import/export data, the top 20 companies' database, and 5 years of forecast.

China pharmaceutical manufacturing industry, 2016 is valuable for anyone who wants to invest in the pharmaceutical manufacturing industry, to get Chinese investments; to import into China or export from China, to build factories and take advantage of lower costs in China, to partner with one of the key Chinese corporations, to get market shares as China is boosting its domestic needs; to forecast the future of the world economy as China is leading the way; or to compete in the segment. The report provides the whole set of the industry data, in-depth analysis and detailed insight into the pharmaceutical manufacturing industry, market drivers, key enterprises and their strategies, as well as technologies and investment status, risks and trends.

Data sources: Governmental statistics organizations, market research (monitoring) centers, industry associations and institutions, import and export statistics organizations, and others.

There are 123 figures and tables in the report.

Report format: PDF

Knowledge is power. If you want to invest in, import into/from, partner with, or compete against any of the companies in this field, then China pharmaceutical manufacturing industry, 2016 is required reading.

This report can be delivered immediately.

Table of Contents

Part I: Industry Overview

1. Definition and development of pharmaceutical manufacturing industry

  • 1.1. Definition of the industry and its core products
    • 1.1.1. Definition of the industry
    • 1.1.2. Core products
  • 1.2. Main characteristics of the industry and a history of its development
    • 1.2.1. Major characteristics of the industry
    • 1.2.2. Course of industrial development

2. Macro environment and impact analysis of pharmaceutical manufacturing industry

  • 2.1. Current macroeconomic developments and trends
    • 2.1.1. China macroeconomic operating environment: 2014
    • 2.1.2. Recommendation on related policies
  • 2.2. Latest industry policies and related laws and regulations
  • 2.3. Development of Upstream and Downstream Industries
    • 2.3.1. Upstream industries
    • 2.3.2. Downstream industries

3. International market analysis of pharmaceutical manufacturing industry

  • 3.1. Current development of its international market
  • 3.2. Levels of development in key countries and regions
    • 3.2.1. United States
    • 3.2.2. United Kingdom

4. Domestic market analysis of pharmaceutical manufacturing industry

  • 4.1. Current development of its domestic market
  • 4.2. Trends in the domestic market

Part 2: Basic indices

5. Size analysis of pharmaceutical manufacturing industry during 2008-2014

  • 5.1. Enterprise number status: 2008-2014
  • 5.2. Number of loss- making enterprises: 2008-2014
  • 5.3. Total loss of the industry: 2008- 2014
  • 5.4. Number of employees: 2008-2014

6. Asset analysis of pharmaceutical manufacturing industry during 2008-2014

  • 6.1. Gross assets of the industry: 2008-2014
  • 6.2. Status of fixed assets: 2008-2014
  • 6.3. Current assets: 2007-2013

Part 3: Economic Operation

7. Gross industrial output value analysis of pharmaceutical manufacturing industry during 2008-2014

  • 7.1. Gross industrial output value: 2008-2014
    • 7.1.1. Overview
    • 7.1.2. By scale
    • 7.1.3. By ownership
  • 7.2. Distribution of gross industrial output value by region: 2014

8. Sales revenue analysis of pharmaceutical manufacturing industry during 2008-2014

  • 8.1. Total industry sales revenue: 2008-2014
    • 8.1.1. Overview
    • 8.1.2. By scale
    • 8.1.3. By ownership
  • 8.2. Distribution of sales revenue by region in 2014

9. Total profits analysis of pharmaceutical manufacturing industry during 2008-2014

  • 9.1. Gross profit analysis: 2008-2014
    • 9.1.1. Overview
    • 9.1.2. By scale
    • 9.1.3. By ownership
  • 9.2. Distribution of total profits by region in 2014

10. Import and export analysis of pharmaceutical manufacturing industry in 2014

  • 10.1. Total import and export analysis of the pharmaceutical manufacturing industry in 2014
  • 10.2. Import and export country analysis of the pharmaceutical manufacturing industry in 2014
  • 10.3. Import and export customs analysis of the pharmaceutical manufacturing industry in 2014
  • 10.4. Import and export region analysis of the pharmaceutical manufacturing industry in 2014

Part 4: Competitive landscape

11. Competitive landscape analysis of pharmaceutical manufacturing industry

  • 11.1. Competitive landscape in the regional markets
  • 11.2. Market share of enterprises in the industry

12. Comparative analysis on the competitiveness of key enterprises in pharmaceutical manufacturing industry

  • 12.1. Comparison for total assets of key enterprises
  • 12.2. Comparison of the number of employees in the key enterprises in the industry
  • 12.3. Comparison for annual operational revenue of key enterprises
  • 12.4. Comparison for export delivery value of key enterprises
  • 12.5. Comparison for total profits of key enterprises
  • 12.6. Comparison for competitiveness of key enterprises

Part 5: Key Enterprises

13. Comparative analysis on the economic indicators of key enterprises in pharmaceutical manufacturing industry

  • 13.1. Yangtze River Pharmaceutical Group Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.2. Harbin Pharmaceutical Group Co., Ltd
    • A Basic information
    • B Analysis of enterprise' business operation
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.3. Jilin Xiuzheng Pharmaceutical Group Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.4. CSPC Pharmaceutical Group Limited
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.5. Weigao Holding Company Limited
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.6. Northeast Pharmaceutical Group Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.7. Bayer HealthCare Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.8. North China Pharmaceutical Group Corp.
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.9. Xinxiang Liuzhuang Agriculture- Industry-Commerce United Company
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.10. Xi'an Janssen Pharmaceutical Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.11. Henan Caixin Group Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.12. Yishui Dadi Corn Developing Co., Ltd
    • A Basic information
    • B Analysis of enterprise' business operation
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.13. Pfizer Pharmaceuticals Limited
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.14. Novo Nordisk (China) Pharmaceuticals Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.15. Tianjin Zhongxin Pharmaceutical Group Corporation Limited
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.16. Reyoung Pharmaceutical Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.17. Shijiazhuang PharmaGroup Zhongrun Pharmaceutical (Inner Mongolia) Co., ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.18. Shanghai Roche Pharmaceuticals Limited
    • A Basic information
    • B Analysis of enterprise' business operation
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.19. Zhejiang Medicine Co., Ltd Xinchang Pharmaceutical Factory
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.20. Huiren Group Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis

Party 6: Operational Strategies

14. Development bottlenecks of the pharmaceutical manufacturing industry and counter strategies

  • 14.1. Development bottleneck of the industry
  • 14.2. Coping strategies of the industry

Part 7: Market Investment

15. Comparison and analysis of investment activity coefficients and investment returns of the pharmaceutical manufacturing industry

  • 15.1. Activity coefficient comparison and analysis of the industry
    • 15.1.1. Related industry activity coefficient comparison in 2014
    • 15.1.2. Activity coefficient of the industry: 2008-2014
    • 15.1.3. Views
  • 15.2. Investment return comparison and analysis of the industry
    • 15.2.1. Comparison of rate of return on investment in related industry: 2014
    • 15.2.2. Analysis on industry rate of return from investment: 2008-2014
    • 15.2.3. Views

16. Analysis of investment environment and investment risks of the pharmaceutical manufacturing industry

  • 16.1. Investment environment of the industry
    • 16.1.1. Financial barriers
    • 16.1.2. Technical barriers
    • 16.1.3. Patent barriers
  • 16.2. Investment risks of the industry
    • 16.2.1. Cyclical risks with new drug R&D
    • 16.2.2. Technological risks with new drug R&D
    • 16.2.3. Risks with industrial qualification and approval
  • 16.3. Investment recommendations

Part 8: Processes and technologies

17. Current situation and trends of the newest technology applications in the pharmaceutical manufacturing industry

  • 17.1. Application of the latest technologies in the industry
  • 17.2. Technological development trend in the industry

Part 9: Development Trends

18. Development trends and operating capability forecast of the pharmaceutical manufacturing industry

  • 18.1. Development trend of the industry
  • 18.2. Industry operating capability forecast: 2015-2019
    • 18.2.1. Total assets forecast: 2015-2019
    • 18.2.2. Total industrial output value forecast of the industry: 2015-2019
    • 18.2.3. Sales revenue forecast: 2015-2019
    • 18.2.4. Total revenue forecast: 2015-2019
Back to Top